Clinical Trials Browser

Phase 1/2 × INDUSTRY × atezolizumab × Clear all

NCT07291076 2026-04-14

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT07227597 2026-04-13

MK-6070-003

Phase 1/2 Recruiting

Small Cell Lung Cancer Extensive Stage

NCT07407933 2026-04-09

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Lung Diseases, Thoracic Neoplasms, Small Cell Lung Carcinoma

NCT03533283 2026-04-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT05440708 2026-04-06

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04524871 2026-03-27

MORPHEUS-LIVER

Phase 1/2 Recruiting

Advanced Liver Cancers

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Phase 1/2 Active not recruiting

Extensive Stage Small Cell Lung Cancer

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT02705196 2026-02-24

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Phase 1/2 Completed

Gastrointestinal

Adenoviridae Infections, Neoplasms, Pancreatic Neoplasms

NCT04471727 2026-02-24

MK-6070-001

Phase 1/2 Active not recruiting

EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT06362252 2026-02-06

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Phase 1/2 Recruiting

Extensive Stage-small Cell Lung Cancer

NCT06939036 2026-02-05

SANTANA-225

Phase 1/2 Terminated

Carcinoma, Merkel Cell

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05450562 2026-01-14

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasms

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT03337698 2025-12-12

Morpheus Lung

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT07280377 2025-12-12

GOBLET

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

NCT05908786 2025-12-11

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT05434234 2025-11-10

A Study of YL201 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Phase 1/2 Terminated

31 enrolled 12 charts

Melanoma, Carcinoma, Merkel Cell

NCT05703971 2025-10-16

Acclaim-3

Phase 1/2 Recruiting

Small Cell Lung Cancer Extensive Stage

NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phase 1/2 Recruiting

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05459129 2025-09-15

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Phase 1/2 Completed

12 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck

NCT02500407 2025-09-12

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Completed

713 enrolled 2 FDA

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05109442 2025-08-20

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Phase 1/2 Terminated

112 enrolled 28 charts

Other solid neoplasm

Advanced Solid Tumor

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05116202 2025-07-18

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Phase 1/2 Completed

110 enrolled 27 charts

Melanoma

NCT03502785 2025-07-10

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Phase 1/2 Completed

Carcinoma, Transitional Cell

NCT04896697 2025-05-29

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1/2 Terminated

222 enrolled 49 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04101357 2025-03-18

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Phase 1/2 Terminated

54 enrolled 30 charts

Small Cell Lung Carcinoma

NCT04440735 2025-01-09

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Phase 1/2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06584071 2024-12-16

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Phase 1/2 Not yet recruiting

Gastrointestinal

Liver Neoplasms

NCT02708680 2024-12-04

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Phase 1/2 Completed

89 enrolled 16 charts

Breast Neoplasms

NCT03730012 2024-11-29

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

11 enrolled 18 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Phase 1/2 Withdrawn

Other solid neoplasm

Select Advanced Solid Tumors

NCT05315713 2024-10-04

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Terminated

8 enrolled 12 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT04123470 2024-09-19

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

Phase 1/2 Completed

24 enrolled 18 charts

Melanoma

NCT03154827 2024-09-05

Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 6 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05240131 2024-04-12

A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02926833 2024-03-06

ZUMA-6

Phase 1/2 Completed

37 enrolled 28 charts

Lymphoma, Large B-Cell, Diffuse

NCT03555149 2023-11-07

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Phase 1/2 Terminated

96 enrolled 24 charts

Gastrointestinal

Colorectal Neoplasms

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1/2 Withdrawn

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT04045613 2023-10-13

FIDES-02

Phase 1/2 Completed

95 enrolled 25 charts

Acrocephalosyndactylia, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03637764 2023-07-10

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Phase 1/2 Terminated

107 enrolled 30 charts

Neoplasms

NCT04471415 2023-06-12

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Phase 1/2 Terminated

Other solid neoplasmThoracic

Advanced Solid Tumor